Sorrento's COVID-19 Main Protease Inhibitor Neutralizes Omicron

·1 min read

Sorrento Therapeutics Inc's (NASDAQ: SRNE) late-stage preclinical Mpro inhibitor, STI-1558, effectively inhibits omicron virus entry and replication in cell-based assays.

  • In VeroE6 cells challenged with omicron variant, STI-1558 alone (without efflux inhibitor) showed significant antiviral activity with an EC50 value of 360 nM, equivalent to that seen against the Delta variant (EC50 value, 370 nM).

  • Related: Sorrento Therapeutics' COVID-19 Antibody Works Against Omicron Variant.

  • In an omicron S protein-mediated pseudovirus entry assay, STI-1558 effectively inhibited pseudovirus entry into cells, whereas EUA-approved Pfizer Inc's (NYSE: PFE) nirmatrelvir (Paxlovid) showed no inhibition.

  • STI-1558 showed improved human liver metabolic stability compared to nirmatrelvir, and its oral bioavailability does not depend on the ritonavir co-administration.

  • Without the need to co-administer Ritonavir, STI-1558 potentially avoids significant adverse drug-drug interactions.

  • Price Action: SRNE shares are down 0.35% at $2.87 during the market session on the last check Friday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting